Lupin Secures Plasil Rights in Philippines, Brazil via Neopharmed Deal

• Lupin's subsidiaries in Philippines (Multicare) and Brazil (MedQuimica) sign exclusive licensing deal with Italy's Neopharmed Gentili.
• Agreement grants marketing and promotional rights for the gastroenterology brand Plasil (metoclopramide) in these markets.
• Aims to strengthen Lupin's gastroenterology portfolio and expand its presence in emerging markets.
• Neopharmed Gentili will manage Plasil supply in the Philippines; production shifts to MedQuimica's facility in Brazil.
• Partnership broadens patient access to Plasil, an effective treatment for nausea, vomiting, and motility disorders.

Why It Matters: Lupin expands its gastroenterology market presence in Philippines and Brazil with Plasil via Neopharmed partnership.